Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)

被引：19

作者：

Poon, S. ^{[1
]}

Birkett, N. R. ^{[1
]}

Fowler, S. B. ^{[2
]}

Luisi, B. F. ^{[3
]}

Dobson, C. M. ^{[1
]}

Zurdo, J. ^{[2
]}

机构：

[1] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England

[2] Zyentia Ltd, Cambridge CB22 3AT, England

[3] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England

来源：

PROTEIN AND PEPTIDE LETTERS | 2009年 / 16卷 / 12期

关键词：

hGLP-1; protein aggregation; biopharmaceuticals; diabetes; amyloid fibrils; Alzheimer's disease; AMYLOID FIBRIL FORMATION; X-RAY-DIFFRACTION; NEURONAL DEGENERATION; THERAPEUTIC PEPTIDE; DIABETES-MELLITUS; GLOBULAR PROTEIN; SELF-ASSOCIATION; HUMAN CALCITONIN; HUMAN-DISEASE; SH3; DOMAIN;

D O I：

10.2174/092986609789839232

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.

引用

页码：1548 / 1556

页数：9

共 50 条

[21] Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Ammann, Markus
Santol, Jonas
Pereyra, David
Kalchbrenner, Tamara
Wuerger, Tanja
Laengle, Johannes
Smoot, Rory L.
Hulla, Wolfgang
Laengle, Friedrich
Starlinger, Patrick
SCIENTIFIC REPORTS, 2023, 13 (01)
[22] Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Markus Ammann
Jonas Santol
David Pereyra
Tamara Kalchbrenner
Tanja Wuerger
Johannes Laengle
Rory L. Smoot
Wolfgang Hulla
Friedrich Laengle
Patrick Starlinger
Scientific Reports, 13
[23] Glucagon-Like Peptide-1 Receptor Agonists
Edelman, Steven V.
JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S12 - S16
[24] Glucagon-like peptide-1, a matter of taste?
Jensterle, Mojca
DeVries, J. Hans
Battelino, Tadej
Battelino, Saba
Yildiz, Bulent
Janez, Andrej
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2021, 22 (04): : 763 - 775
[25] Glucagon-Like Peptide-1 Gene Therapy
Rowzee, Anne M.
Cawley, Niamh X.
Chiorini, John A.
Di Pasquale, Giovanni
EXPERIMENTAL DIABETES RESEARCH, 2011,
[26] Is ghrelin a glucagon-like peptide-1 secretagogue?
Ueno, Hiroaki
Nakazato, Masamitsu
JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 466 - 467
[27] Glucagon-like peptide-1 and safety - Reply
Bloom, SR
NATURE, 1997, 385 (6613) : 214 - 214
[28] Glucagon-Like Peptide-1 and Diabetes 2012
Monami, Matteo
Di Pasquale, Giovanni
Rowzee, Anna
Rotella, Carlo Maria
Mannucci, Edoardo
EXPERIMENTAL DIABETES RESEARCH, 2012,
[29] Glucagon-like peptide-1 and islet lipolysis
Winzell, MS
Ahrén, B
HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 795 - 803
[30] Glucagon-like peptide-1 and energy homeostasis
Burcelin, Remy
Cani, Patrice D.
Knauf, Claude
JOURNAL OF NUTRITION, 2007, 137 (11): : 2534S - 2538S

← 1 2 3 4 5 →